with sucess

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت

2004 noting, in connection with a private lawsuit involving the same settlement agreements challenged by the FTC in Schering Plough, that the plaintiffs alleged that the generic manufacturer not only agreed not to enter the market with the allegedly infringing generic drug at issue in the patent litigation, but agreed not to enter the market with any generic competitor drug, irrespective of whether it infringed the patent and that another potential distributor of generic equivalents also agreed to delay marketing a generic competitor drug and agreed not to conduct, sponsor, file or support any study of a generic drug s bioequivalence to the patented drug before the expiration of the relevant patent, and concluding These agreements, as alleged, grant rights to Schering in excess of what is granted by the relevant patent alone